vs
Embecta Corp.（EMBC）与Revolve Group, Inc.（RVLV）财务数据对比。点击上方公司名可切换其他公司
Revolve Group, Inc.的季度营收约是Embecta Corp.的1.2倍（$324.4M vs $261.2M），Embecta Corp.净利率更高（16.9% vs 5.7%，领先11.2%），Revolve Group, Inc.同比增速更快（10.4% vs -0.3%），Embecta Corp.自由现金流更多（$16.6M vs $-13.3M），过去两年Revolve Group, Inc.的营收复合增速更高（9.5% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
Revolve Theatre Company是总部位于英国泰晤士河畔亨利的剧团，专注于创作演出政治题材和莎士比亚系列戏剧作品，由奥利弗·登奇、乔·莫里斯与汤姆·史密斯共同创立运营。
EMBC vs RVLV — 直观对比
营收规模更大
RVLV
是对方的1.2倍
$261.2M
营收增速更快
RVLV
高出10.7%
-0.3%
净利率更高
EMBC
高出11.2%
5.7%
自由现金流更多
EMBC
多$29.9M
$-13.3M
两年增速更快
RVLV
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $324.4M |
| 净利润 | $44.1M | $18.6M |
| 毛利率 | 61.9% | 53.3% |
| 营业利润率 | 31.9% | 6.3% |
| 净利率 | 16.9% | 5.7% |
| 营收同比 | -0.3% | 10.4% |
| 净利润同比 | — | 50.4% |
| 每股收益（稀释后） | $0.74 | $0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCRVLV
| Q4 25 | $261.2M | $324.4M | ||
| Q3 25 | $264.0M | $295.6M | ||
| Q2 25 | $295.5M | $309.0M | ||
| Q1 25 | $259.0M | $296.7M | ||
| Q4 24 | $261.9M | $293.7M | ||
| Q3 24 | $286.1M | $283.1M | ||
| Q2 24 | $272.5M | $282.5M | ||
| Q1 24 | $287.2M | $270.6M |
净利润EMBCRVLV
| Q4 25 | $44.1M | $18.6M | ||
| Q3 25 | $26.4M | $21.2M | ||
| Q2 25 | $45.5M | $10.2M | ||
| Q1 25 | $23.5M | $11.8M | ||
| Q4 24 | $0 | $12.3M | ||
| Q3 24 | $14.6M | $11.0M | ||
| Q2 24 | $14.7M | $15.4M | ||
| Q1 24 | $28.9M | $10.9M |
毛利率EMBCRVLV
| Q4 25 | 61.9% | 53.3% | ||
| Q3 25 | 60.0% | 54.6% | ||
| Q2 25 | 66.7% | 54.1% | ||
| Q1 25 | 63.4% | 52.0% | ||
| Q4 24 | 60.0% | 52.5% | ||
| Q3 24 | 60.7% | 51.2% | ||
| Q2 24 | 69.8% | 54.0% | ||
| Q1 24 | 64.6% | 52.3% |
营业利润率EMBCRVLV
| Q4 25 | 31.9% | 6.3% | ||
| Q3 25 | 21.4% | 7.1% | ||
| Q2 25 | 31.8% | 5.8% | ||
| Q1 25 | 24.3% | 5.0% | ||
| Q4 24 | 11.0% | 3.9% | ||
| Q3 24 | 9.2% | 5.0% | ||
| Q2 24 | 20.5% | 5.8% | ||
| Q1 24 | 13.6% | 3.4% |
净利率EMBCRVLV
| Q4 25 | 16.9% | 5.7% | ||
| Q3 25 | 10.0% | 7.2% | ||
| Q2 25 | 15.4% | 3.3% | ||
| Q1 25 | 9.1% | 4.0% | ||
| Q4 24 | — | 4.2% | ||
| Q3 24 | 5.1% | 3.9% | ||
| Q2 24 | 5.4% | 5.4% | ||
| Q1 24 | 10.1% | 4.0% |
每股收益（稀释后）EMBCRVLV
| Q4 25 | $0.74 | $0.27 | ||
| Q3 25 | $0.44 | $0.29 | ||
| Q2 25 | $0.78 | $0.14 | ||
| Q1 25 | $0.40 | $0.16 | ||
| Q4 24 | $0.00 | $0.18 | ||
| Q3 24 | $0.24 | $0.15 | ||
| Q2 24 | $0.25 | $0.21 | ||
| Q1 24 | $0.50 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $292.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-613.1M | $512.5M |
| 总资产 | $1.1B | $765.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EMBCRVLV
| Q4 25 | $201.3M | $292.3M | ||
| Q3 25 | $225.5M | $315.4M | ||
| Q2 25 | $230.6M | $310.7M | ||
| Q1 25 | $209.3M | $300.8M | ||
| Q4 24 | $210.0M | $256.6M | ||
| Q3 24 | $267.5M | $252.8M | ||
| Q2 24 | $275.1M | $244.7M | ||
| Q1 24 | $299.8M | $273.4M |
总债务EMBCRVLV
| Q4 25 | — | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EMBCRVLV
| Q4 25 | $-613.1M | $512.5M | ||
| Q3 25 | $-650.6M | $490.2M | ||
| Q2 25 | $-669.6M | $468.6M | ||
| Q1 25 | $-736.2M | $453.4M | ||
| Q4 24 | $-768.8M | $437.8M | ||
| Q3 24 | $-738.3M | $420.8M | ||
| Q2 24 | $-763.7M | $405.8M | ||
| Q1 24 | $-769.6M | $389.9M |
总资产EMBCRVLV
| Q4 25 | $1.1B | $765.0M | ||
| Q3 25 | $1.1B | $751.3M | ||
| Q2 25 | $1.2B | $722.9M | ||
| Q1 25 | $1.1B | $713.9M | ||
| Q4 24 | $1.1B | $665.5M | ||
| Q3 24 | $1.3B | $670.9M | ||
| Q2 24 | $1.3B | $657.8M | ||
| Q1 24 | $1.2B | $650.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $-10.2M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | $-13.3M |
| 自由现金流率自由现金流/营收 | 6.4% | -4.1% |
| 资本支出强度资本支出/营收 | 0.2% | 1.0% |
| 现金转化率经营现金流/净利润 | 0.39× | -0.55× |
| 过去12个月自由现金流最近4个季度 | $205.8M | $48.0M |
8季度趋势，按日历期对齐
经营现金流EMBCRVLV
| Q4 25 | $17.2M | $-10.2M | ||
| Q3 25 | $84.0M | $11.8M | ||
| Q2 25 | $81.2M | $12.6M | ||
| Q1 25 | $31.8M | $45.1M | ||
| Q4 24 | $-5.3M | $3.9M | ||
| Q3 24 | $26.6M | $9.1M | ||
| Q2 24 | $-2.1M | $-24.7M | ||
| Q1 24 | $24.3M | $38.4M |
自由现金流EMBCRVLV
| Q4 25 | $16.6M | $-13.3M | ||
| Q3 25 | $76.7M | $7.5M | ||
| Q2 25 | $80.8M | $10.4M | ||
| Q1 25 | $31.7M | $43.4M | ||
| Q4 24 | $-6.8M | $2.1M | ||
| Q3 24 | — | $8.0M | ||
| Q2 24 | $-11.8M | $-25.7M | ||
| Q1 24 | $20.9M | $36.7M |
自由现金流率EMBCRVLV
| Q4 25 | 6.4% | -4.1% | ||
| Q3 25 | 29.1% | 2.5% | ||
| Q2 25 | 27.3% | 3.4% | ||
| Q1 25 | 12.2% | 14.6% | ||
| Q4 24 | -2.6% | 0.7% | ||
| Q3 24 | — | 2.8% | ||
| Q2 24 | -4.3% | -9.1% | ||
| Q1 24 | 7.3% | 13.5% |
资本支出强度EMBCRVLV
| Q4 25 | 0.2% | 1.0% | ||
| Q3 25 | 2.8% | 1.5% | ||
| Q2 25 | 0.1% | 0.7% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.6% | 0.6% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | 3.6% | 0.4% | ||
| Q1 24 | 1.2% | 0.6% |
现金转化率EMBCRVLV
| Q4 25 | 0.39× | -0.55× | ||
| Q3 25 | 3.18× | 0.56× | ||
| Q2 25 | 1.78× | 1.24× | ||
| Q1 25 | 1.35× | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | 1.82× | 0.83× | ||
| Q2 24 | -0.14× | -1.60× | ||
| Q1 24 | 0.84× | 3.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
